131 related articles for article (PubMed ID: 26366217)
1. The Expression and Function of NUMB in Endometrial Cancer and the Interaction with HDM2 and P53.
Wang C; Feng W; Zhang C
J Cancer; 2015; 6(10):1030-40. PubMed ID: 26366217
[TBL] [Abstract][Full Text] [Related]
2. Role of Numb expression and nuclear translocation in endometrial cancer.
Wang C; Cui T; Feng W; Li H; Hu L
Oncol Lett; 2015 Apr; 9(4):1531-1536. PubMed ID: 25788995
[TBL] [Abstract][Full Text] [Related]
3. Progress in the research of p53 tumour suppressor activity controlled by Numb in triple-negative breast cancer.
Xian J; Cheng Y; Qin X; Cao Y; Luo Y; Cao Y
J Cell Mol Med; 2020 Jul; 24(13):7451-7459. PubMed ID: 32501652
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B e antigen and its precursors promote the progress of hepatocellular carcinoma by interacting with NUMB and decreasing p53 activity.
Liu D; Cui L; Wang Y; Yang G; He J; Hao R; Fan C; Qu M; Liu Z; Wang M; Chen L; Li H; Guo D
Hepatology; 2016 Aug; 64(2):390-404. PubMed ID: 27106262
[TBL] [Abstract][Full Text] [Related]
5. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
Phelps M; Darley M; Primrose JN; Blaydes JP
Cancer Res; 2003 May; 63(10):2616-23. PubMed ID: 12750288
[TBL] [Abstract][Full Text] [Related]
6. [The relationship and clinicopathological significance of Numb,MDM2 and p53 expression in human pancreatic cancer].
Sheng W; Dong M; Zhou J; Li X; Liu Q; Dong Q; Li F
Zhonghua Wai Ke Za Zhi; 2014 Sep; 52(9):675-81. PubMed ID: 25410780
[TBL] [Abstract][Full Text] [Related]
7. Expression of cyclooxygenase-2 in colorectal adenocarcinoma is associated with p53 accumulation and hdm2 overexpression.
Cressey R; Pimpa S; Tontrong W; Watananupong O; Leartprasertsuke N
Cancer Lett; 2006 Feb; 233(2):232-9. PubMed ID: 15921850
[TBL] [Abstract][Full Text] [Related]
8. HDM2 and HDMX Proteins in Human Cancer.
Hároníková L; Vojtěšek B
Klin Onkol; 2018; 31(Suppl 2):63-70. PubMed ID: 31023026
[TBL] [Abstract][Full Text] [Related]
9. p14ARF expression in invasive breast cancers and ductal carcinoma in situ--relationships to p53 and Hdm2.
Vestey SB; Sen C; Calder CJ; Perks CM; Pignatelli M; Winters ZE
Breast Cancer Res; 2004; 6(5):R571-85. PubMed ID: 15318938
[TBL] [Abstract][Full Text] [Related]
10. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma.
Mori S; Ito G; Usami N; Yoshioka H; Ueda Y; Kodama Y; Takahashi M; Fong KM; Shimokata K; Sekido Y
Cancer; 2004 Apr; 100(8):1673-82. PubMed ID: 15073856
[TBL] [Abstract][Full Text] [Related]
11. HDM2 overexpression and focal loss of p14/ARF expression may deregulate the p53 tumour suppressor pathway in meningeal haemangiopericytomas. Study by double immunofluorescence and laser scanning confocal microscopy.
Martínez JC; Palomino JC; Cabello A; Sepúlveda JM; de la Cámara AG; Ricoy JR
Histopathology; 2005 Feb; 46(2):184-94. PubMed ID: 15693891
[TBL] [Abstract][Full Text] [Related]
12. NUMB controls p53 tumour suppressor activity.
Colaluca IN; Tosoni D; Nuciforo P; Senic-Matuglia F; Galimberti V; Viale G; Pece S; Di Fiore PP
Nature; 2008 Jan; 451(7174):76-80. PubMed ID: 18172499
[TBL] [Abstract][Full Text] [Related]
13. The oncoprotein SS18-SSX1 promotes p53 ubiquitination and degradation by enhancing HDM2 stability.
D'Arcy P; Maruwge W; Ryan BA; Brodin B
Mol Cancer Res; 2008 Jan; 6(1):127-38. PubMed ID: 18234968
[TBL] [Abstract][Full Text] [Related]
14. Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization.
Giglio S; Mancini F; Gentiletti F; Sparaco G; Felicioni L; Barassi F; Martella C; Prodosmo A; Iacovelli S; Buttitta F; Farsetti A; Soddu S; Marchetti A; Sacchi A; Pontecorvi A; Moretti F
Cancer Res; 2005 Nov; 65(21):9687-94. PubMed ID: 16266988
[TBL] [Abstract][Full Text] [Related]
15. Nucleolar p14(ARF) overexpression in Reed-Sternberg cells in Hodgkin's lymphoma: absence of p14(ARF)/Hdm2 complexes is associated with expression of alternatively spliced Hdm2 transcripts.
García JF; Villuendas R; Sánchez-Beato M; Sánchez-Aguilera A; Sánchez L; Prieto I; Piris MA
Am J Pathol; 2002 Feb; 160(2):569-78. PubMed ID: 11839577
[TBL] [Abstract][Full Text] [Related]
16. BCL11B tumor suppressor inhibits HDM2 expression in a p53-dependent manner.
Obata M; Kominami R; Mishima Y
Cell Signal; 2012 May; 24(5):1047-52. PubMed ID: 22245141
[TBL] [Abstract][Full Text] [Related]
17. Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hits.
Dudgeon DD; Shinde S; Hua Y; Shun TY; Lazo JS; Strock CJ; Giuliano KA; Taylor DL; Johnston PA; Johnston PA
J Biomol Screen; 2010 Aug; 15(7):766-82. PubMed ID: 20639499
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.
Li LH; Zhang PR; Cai PY; Li ZC
Biomed Pharmacother; 2016 Aug; 82():161-6. PubMed ID: 27470351
[TBL] [Abstract][Full Text] [Related]
19. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium.
Ioffe OB; Papadimitriou JC; Drachenberg CB
Hum Pathol; 1998 Oct; 29(10):1150-9. PubMed ID: 9781657
[TBL] [Abstract][Full Text] [Related]
20. Abundant expression of spliced HDM2 in Hodgkin lymphoma cells does not interfere with p14(ARF) and p53 binding.
Stürzenhofecker B; Schlott T; Quentin T; Kube D; Jung W; Trümper L
Leuk Lymphoma; 2003 Sep; 44(9):1587-96. PubMed ID: 14565663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
